Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

     

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MVzDfZRwfG:6aXPpeJkhSXO|YYm= NV3Oe2Q5OOLCk{G2NOKh|ryP NXPGNYRuPDkEoHi= NFTTSo1KSzVyPUWuPOKhyrIEoECuOUDPxE1? MWWyOlQ4PDZ7Mx?=
CaES-17 MW\DfZRwfG:6aXPpeJkhSXO|YYm= MWmw5qCUOTZywrFOwG0> M1qwZVQ5yqCq MUXJR|UxRTVwNdMgxtHDqDBwMjFOwG0> M3u3TlI3PDd2Nkmz
SW480 NH3tVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXGRYpCPDhiaNMg MUHJR|UxRTFwOEeg{txO MYCyOlI3QTd3OR?=
HCT116 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0PEBpyqB? NUnDOlZqUUN3ME2xNU45PiEQvF2= NU[0V|N2OjZ{Nkm3OVk>
LoVo NYnrN5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWK0PEBpyqB? NEnrZ|VKSzVyPUm0Mlg{KM7:TR?= M3vqW|I3OjZ7N{W5
SK-BR-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHVNJBTUUN3ME2zNU4xKMLzIECuNUDPxE1? MWSyOlIyOTV7MR?=
MCF-7 M4q4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF3LkSgxtEhOC5|IN88US=> NFi3bIkzPjJzMUW5NS=>
MDA-MB-231 MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTJ|LkGgxtEhOC5zIN88US=> M2DNTFI3OjFzNUmx
HCT116 p53+/+ M1fUc2Z2dmO2aX;uJGF{e2G7 Mlm1NU82KM7:TR?= NYXwSWJEOjRxNEigbC=> M1;2[4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= NVTqWHRKOjZ{MEi1NlM>
LoVo  NUHl[GgxTnWwY4Tpc44hSXO|YYm= MnXTNU82KM7:TR?= M3vtZVI1NzR6IHi= NX;zN4kxcW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> M4DtWlI3OjB6NUKz
SNU-398 NU\VOZpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXuV4VzUUN3ME22MlXDqMLzwrCxMlEh|ryP NULFXnBzOjZzNkC0Nlk>
Hep-G2 NHj2VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvlfXpKSzVyPUGzMlHDqMLzwrCxMlYh|ryP M4C5ZVI3OTZyNEK5
SNU-475 MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|Ux97zgM{Cg{txO MnLSNlYyPjB2Mkm=
SNU-387 NXjoZpdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfnXVBKUUN3ME2yOeKhyrIEoEKuO{DPxE1? MU[yOlE3ODR{OR?=
HT29 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\yNmlEPTB;MD64POKhyrIEoECuNkDPxE1? M2LpdlI3OTR6NUm2
HCT116 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml74TWM2OD1yLkSxxsDDucLiMD6wNkDPxE1? M1\VXVI3OTR6NUm2
PA-1 MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3mwWFAuOjBizszN NGHheZYzPC92ODDo MnfPbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M3zqTlI3OTN6Nkex
OVCAR-5 Mni0R4VtdCCYaXHibYxqfHliQYPzZZk> MYSwMVYxKM7:TR?= NIDnRlgzPC92OD:3NkBp NHK4NGdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGPQVJkzPjF|OE[3NS=>
SK-OV-3 NH3PWI9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHTjWmIxNTFyMDFOwG0> NH3M[WQzPC92OD:3NkBp MnHObY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MnjNNlYyOzh4N{G=
PA-1 M321emZ2dmO2aX;uJGF{e2G7 MV2xNEDPxE4EoB?= M{mweVI1cA>? NFfZZ|l1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NF\pZWYzPjF|OE[3NS=>
OVCAR-5 MVjGeY5kfGmxbjDBd5NigQ>? NHHt[IY{OCEQvF2= NGPuUIk1QGh? NVnDU4p7fHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ Mln3NlYyOzh4N{G=
SK-OV-3 NX20VVZLTnWwY4Tpc44hSXO|YYm= NG\2TYs2OCEQvF2= MVe5OkBp NE\GWYd1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> M3nxcVI3OTN6Nkex
PA-1 MkSxSpVv[3Srb36gRZN{[Xl? M4P0blExKM7:TdMg MWS0PIg> MVz1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> NYToVYZjOjZzM{i2O|E>
OVCAR-5 NVrLb3NzTnWwY4Tpc44hSXO|YYm= MoSxN|Ah|ryP NFT1fYw1QGh? NF;jPIt2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? Mo\WNlYyOzh4N{G=
SK-OV-3 NFzHR|lHfW6ldHnvckBCe3OjeR?= M3jsb|UxKM7:TR?= MYC5OkBp M1O1e5VxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? MnPPNlYyOzh4N{G=
PA-1 M3H6PGZ2dmO2aX;uJGF{e2G7 NVPuSZppOTBizszNxsA> NHvLOZYzPGh? M2q2bpBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz NW\Tc|VtOjZzM{i2O|E>
OVCAR-5 NYrnNm0{TnWwY4Tpc44hSXO|YYm= NX;yVHl5OjBizszNxsA> NYjzZYFQOjSq NVe0bWpreHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MlrwNlYyOzh4N{G=
SK-OV-3 Mm\kSpVv[3Srb36gRZN{[Xl? NEey[pg2OCEQvF5CpC=> MnWzOFghcMLi NV36fVY2eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> NUfMUJlvOjZzM{i2O|E>
CT26  NHWzNnRHfW6ldHnvckBCe3OjeR?= NGDWVog1KG2P NEDYRVA1QCCqwrC= NU\6T2dtcW6mdXPld{BifXSxcHjh[5k> MkGzNlYyOzdyMUK=
CT26  M4\WTmZ2dmO2aX;uJGF{e2G7 NE\FO5o1KG2P MoHOOFghcMLi MnjRbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVteyCxZjDheZRweGijZ4mtdoVt[XSnZDDwdo91\Wmwczygd5VkcCCjczDMR|MuUUluIFLlZ4xqdjFiYX7kJGFVTzV? M2jzeFI3OTN5MEGy
CT26  NHzvO4pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2Pm[lQhdU1? M3KxUVQ5KGkEoB?= MUXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? MnnrNlYyOzdyMUK=
BE M2fldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnzTWM2OD1|LkOzJO69VQ>? NUHTZWk5OjZyMkOwPFU>
Colo205 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXQWHdKSzVyPUOuN|Mh|ryP Mn7sNlYxOjNyOEW=
DLD1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPTbVVKSzVyPUKuNFEh|ryP M1fRU|I3ODJ|MEi1
HT29 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET0W3dKSzVyPUKuOlkh|ryP Mn\jNlYxOjNyOEW=
HCT15 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fqNWlEPTB;MT60N{DPxE1? NWDiTJV{OjZyMkOwPFU>
HCT116 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrEToNKSzVyPUGuNFQh|ryP MkjENlYxOjNyOEW=
HCT116p53- MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfBNHRuUUN3ME2xMlA5KM7:TR?= MW[yOlAzOzB6NR?=
KM12 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwM{eg{txO NGfococzPjB{M{C4OS=>
LoVo M1vFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwMjFOwG0> MUmyOlAzOzB6NR?=
RKO NV\PU3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrjTWM2OD1zLkKzJO69VQ>? MnS2NlYxOjNyOEW=
SW480 NVTVVWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvPTWM2OD1{Lki2JO69VQ>? MWeyOlAzOzB6NR?=
SW620 NHi2TZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;QTWM2OD1|Lk[4JO69VQ>? NV:xbXU3OjZyMkOwPFU>
MC38 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTrcm9KSzVyPUKzJO69VSEEsTCy M4LIPFI3ODB2MEi0
HT29 NGfCfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml72TWM2OD14MzFOwG0hyrFiMUi= MYeyOlAxPDB6NB?=
DLD-1 NXGw[HJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq4TWM2OD1|Mj6yJO69VQ>? M4C3NVI3ODB|MEi1
HT-29 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\wSmlEPTB;M{WuOkDPxE1? NH\HdpkzPjByM{C4OS=>
SiHa NGH1SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljyTWM2OD1yLkigxtEhOC5zIN88US=> NEfKWWMzPThyMUCwOy=>
S3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTV|LkWgxtEhOS53IN88US=> NF\tZnozPThyMUCwOy=>
AGS NYm3dHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\EVHpKSzVyPUGwMlYh|ryP MXWyOVc5QTB3Nx?=
MKN-45 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zSXWlEPTB;MUSuNEDPxE1? MWmyOVc5QTB3Nx?=
TMK-1 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jT[2lEPTB;MkKuOkDPxE1? M3O0VlI2Pzh7MEW3
SCM-1 NXnuVYUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF5LkWg{txO NEHS[JgzPTd6OUC1Oy=>
HCT-15 MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjmTWM2OD16Lk[0JO69VQ>? M3W3[lI2PzZzNEe5
DiFi MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PQNGlEPTB;MUCuPVUh|ryP M{DNVFI2PzZzNEe5
DLD-1 NXGzPWpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTyTWM2OD16Lk[1JO69VQ>? M4LweFI2PzZzNEe5
COLO-320DM M2XOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnriTWM2OD13LkO4JO69VQ>? NYS1enlSOjV5NkG0O|k>
SNU-175 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLHOWx5UUN3ME2xMlUyKM7:TR?= MVuyOVc3OTR5OR?=
HT-29 MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTVwMkKg{txO M2W4ZlI2PzZzNEe5
SW620 NHixdlVHfW6ldHnvckBCe3OjeR?= Mk\hNVDjiIoEtXevcYw> NH7nPIwzPOLCiXi= NF;O[mFqdmO{ZXHz[ZMhVEN|LVnJJIFk[3WvdXzheIlwdiCjbnSg[IVkemWjc3XzJHA3OiCneIDy[ZN{cW:w M1\RRVI2PzR7NEKw
SW480 NYnZeZRmTnWwY4Tpc44hSXO|YYm= M1\OTFEx6oDLwsXnM41t M3\x[|I16oDLaB?= M4riV4lv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? NUXHfVdsOjV5NEm0NlA>
SW620 NIO0V|NHfW6ldHnvckBCe3OjeR?= M3\iXVEx6oDLwsXnM41t MXuyOQKBkWh? NET6SpZmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= MojQNlU4PDl2MkC=
SW480 NHTHbnVHfW6ldHnvckBCe3OjeR?= MV6xNQKBkcL3Zz;tcC=> M{DNRlI16oDLaB?= NIfzUXVmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi= NHnjRY8zPTd2OUSyNC=>
A549 NV;CUXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD13LkigxtEhOC54IN88US=> NHXiV|kzPTZ{NUK0Ny=>
A549/CDDP MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3wTWM2OD1zOD62JOKyKDFwMjFOwG0> NXz0RlR7OjV4MkWyOFM>
Panc-1 MlSzR4VtdCCYaXHibYxqfHliQYPzZZk> NYrQOm1NOjVxNUCg{txO NUTIXHpTOjRxNEigbC=> NXm0UVdScW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MojrNlU1PDR7MUS=
MIAPaCa-2 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUOyOU82OCEQvF2= MnrKNlQwPDhiaB?= MnnxbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MUKyOVQ1PDlzNB?=
SW1990 NV71VFlmS2WubDDWbYFjcWyrdImgRZN{[Xl? MorVNlUwPTBizszN NE[4bmczPC92ODDo M2XQb4lvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NUK0dmtmOjV2NES5NVQ>
HPDE MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUmyOU82OCEQvF2= MX:yOE81QCCq M3zxTIlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? NYTR[Y11OjV2NES5NVQ>
Panc-1 MnPCRZBweHSxc3nzJGF{e2G7 M13HTFI26oDLwsXN M3H0dlI1KGh? NH7NcVhqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NUPGN2pqOjV2NES5NVQ>
MIAPaCa-2 M13pNGFxd3C2b4Ppd{BCe3OjeR?= NWK2OmFpOjYkgJpCuW0> NUmxS|lZOjRiaB?= MY\pcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC NE[5S|AzPTR2NEmxOC=>
Panc-1 MYnGeY5kfGmxbjDBd5NigQ>? MoDQNlXjiIoEtV2= NGT3WJUzPC92ODDo MULpcoR2[2W|IHPs[YF3[WenIH;mJHBCWlBuIHPhd5Bie2VvOTygZ4F{eGG|ZT24JIFv\CClYYPwZZNmNTQEoB?= MV2yOVQ1PDlzNB?=
MIAPaCa-2 NVXwc5U4TnWwY4Tpc44hSXO|YYm= NUexOXYzOjYkgJpCuW0> MmX3NlQwPDhiaB?= M3jSOIlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NIHiWIMzPTR2NEmxOC=>
SW480 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEixbJo4OiCqwrC= MYLJR|UxRTFyLkhCtVIvOjZiwsXnM41N M{PK[VI2OzZyNkOx
HCT116  M376Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1[JA4OiCqwrC= NGj2[IhKSzVyPU[uNlPDuTBwN{WgxtVoN22O MnnwNlU{PjB4M{G=
COC1 NHTQRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG5ZVdKSzVyPUS2MlIxyqEEsdMgN{4yPCEQvF2= Mn7WNlU{ODd2NEi=
SGC7901 NHHRSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzwZppsUUN3ME2yNU44O8LiwsJCpFMvODhizszN MWSyOVMxPzR2OB?=
A549 NVvaTI5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTVzLkC4xsDDucLiMUCuPVYh|ryP M{fM[FI2OzB5NES4
HepG2 NV\lR4NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TOTWlEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= MnfRNlU{ODd2NEi=
MCF-7 NFy0Uo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnGSnlKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= MV6yOVMxPzR2OB?=
HCT-116 NVrZT5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj2[GxDUUN3ME22MlI1yqEEsdMgNk46PyEQvF2= NFjk[oMzPTNyN{S0PC=>
HT-29 Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj2cINKSzVyPkWwJO69VQ>? MX6yOVMxPzR2OB?=
HEK293 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DFNWlEPTB;OD64NuKhyrIEoEWuOVkh|ryP M3zJRVI2OzB5NES4
HUVEC NGj3SIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\1U2lEPTB;MUGuN|DDqMLzwrCxMlAzKM7:TR?= NIflPWszPTNyN{S0PC=>
SW480 NH\mVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q2NVHDqM7:TR?= NVPOc4NmOC15MjDo NUXiXo5RcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? MYiyOFk6PzR3MR?=
HT-29 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C1dVHDqM7:TR?= NWXqZZRpOC15MjDo NVHuUGI3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? NF[0UXgzPDl7N{S1NS=>
HCT116 M2HydmZ2dmO2aX;uJGF{e2G7 MXiyM|UhyrWP NFrwWGYzPC92ODDo NGi0V3F{fXCycnXzd4V{KHO3co\peolvKG2UTlGg[ZhxemW|c3nvci=> Ml\vNlQ4PjF2MUG=
SW480  Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTUOFghcMLi NVTkOIZJUUN3ME2yNE45KHWpL33M MXmyOFczODZ5NR?=
SW620 M4i2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ldHRROTBvN{CgcYcwVA>? M1vRfFI1NzR6L{eyJIg> NGDJO2NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M2\DcVI1PjR4M{C1
Caco2  NEXI[ZRHfW6ldHnvckBCe3OjeR?= M2H2blMxyqEQvF2= NFewSXAzPCCq Ml34SG1UVw>? NITkS3ZqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? Mk\hNlQ2PTZ2MUW=
Caco2  MnTtSpVv[3Srb36gRZN{[Xl? NITucpk{NzFyL{OwJO69VQ>? MlzsNVYhcA>? NVjhe29RTE2VTx?= M1;4bolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> M{\RdVI1PTV4NEG1
Caco2 NG\SXXpHfW6ldHnvckBCe3OjeR?= MojuN|AwOTBywrFOwG0> MoPvNVbDqGh? MonkSG1UVw>? Mn\2ZYN1cX[jdHXzJG5z\jJ? MmHDNlQ2PTZ2MUW=

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order:
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT03050814 Not yet recruiting Colorectal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 2017 Phase 2
NCT02997228 Not yet recruiting Colorectal Adenocarcinoma|High-Frequency Microsatellite Instability|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) November 2017 Phase 3
NCT02912559 Not yet recruiting Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Microsatellite Instability|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer National Cancer Institute (NCI) September 2017 Phase 3
NCT03043729 Not yet recruiting Rectal Cancer|Rectosigmoid Cancer AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi February 2017 Phase 2
NCT03000374 Not yet recruiting Rectal Cancer Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID